[New drug approval: Olaparib and niraparib - first line in ovarian cancer]

Bull Cancer. 2021 Apr;108(4):350-351. doi: 10.1016/j.bulcan.2021.01.003. Epub 2021 Feb 26.
[Article in French]
No abstract available

Keywords: BRCA; Cancers de l’ovaire; Inhibiteurs de PARP; Recombinaison homologue.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Approval
  • Female
  • Humans
  • Indazoles / therapeutic use*
  • Ovarian Neoplasms / drug therapy*
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Piperidines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

  • Antineoplastic Agents
  • Indazoles
  • Phthalazines
  • Piperazines
  • Piperidines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • niraparib
  • olaparib